MCID: PRV006
MIFTS: 50

Pervasive Developmental Disorder

Categories: Mental diseases

Aliases & Classifications for Pervasive Developmental Disorder

MalaCards integrated aliases for Pervasive Developmental Disorder:

Name: Pervasive Developmental Disorder 12 52 14
Pervasive Development Disorder 12 69
Pervasive Developmental Disorders 51
Autism Spectrum Disorders 69
Autistic Behavior 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060040
ICD9CM 35 299.80
ICD10 33 F84
UMLS 69 C0154451

Summaries for Pervasive Developmental Disorder

NINDS : 51 The diagnostic category of pervasive developmental disorders (PDD) refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of onset is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns. Autism (a developmental brain disorder characterized by impaired social interaction and communication skills, and a limited range of activities and interests) is the most characteristic and best studied PDD. Other types of PDD include Asperger's Syndrome, Childhood Disintegrative Disorder, and Rett's Syndrome. Children with PDD vary widely in abilities, intelligence, and behaviors. Some children do not speak at all, others speak in limited phrases or conversations, and some have relatively normal language development. Repetitive play skills and limited social skills are generally evident. Unusual responses to sensory information, such as loud noises and lights, are also common.

MalaCards based summary : Pervasive Developmental Disorder, also known as pervasive development disorder, is related to atypical autism and pervasive developmental disorder not otherwise specified, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Pervasive Developmental Disorder is MECP2 (Methyl-CpG Binding Protein 2), and among its related pathways/superpathways are Neuroscience and Transmission across Chemical Synapses. The drugs Aripiprazole and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased viability after Maraba virus infection and behavior/neurological

Disease Ontology : 12 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors.

Wikipedia : 72 The diagnostic category pervasive developmental disorders (PDD), as opposed to specific developmental... more...

Related Diseases for Pervasive Developmental Disorder

Diseases related to Pervasive Developmental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Related Disease Score Top Affiliating Genes
1 atypical autism 26.9 CHD8 CNTNAP2 CTNND2 EIF4E FMR1 FOXP2
2 pervasive developmental disorder not otherwise specified 12.4
3 autism spectrum disorder 11.8
4 asperger syndrome 11.2
5 childhood disintegrative disease 11.2
6 landau-kleffner syndrome 11.1
7 autism susceptibility 17 11.0
8 autism 18 11.0
9 autism susceptibility, x-linked 2 11.0
10 autism x-linked 4 11.0
11 autism susceptibility 16 11.0
12 autism susceptibility, x-linked 1 11.0
13 autism susceptibility, x-linked 3 11.0
14 autism x-linked 5 11.0
15 autism x-linked 6 11.0
16 autism susceptibility 15 11.0
17 autism 9 10.9
18 autism 10 10.9
19 autistic disorder 10.9
20 xeroderma pigmentosum, type 9 10.8 MECP2 NLGN4X PTCHD1
21 specific developmental disorder 10.8
22 potocki-lupski syndrome 10.8
23 mental retardation, autosomal recessive 41 10.8
24 autism 19 10.8
25 potocki-luspski syndrome 10.8
26 chromosome 16p11.2 deletion syndrome, 220-kb 10.8
27 rett syndrome 10.8
28 paraphilia disorder 10.7 NLGN3 NLGN4X
29 childhood-onset nemaline myopathy 10.7 CNTNAP2 FOXP2
30 hyperglycemia 10.6 CNTNAP2 SHANK3
31 tendinopathy 10.6 CNTNAP2 FOXP2 MECP2
32 paroxysmal nonkinesigenic dyskinesia 1 10.5 FMR1 MECP2 SHANK3
33 hyperthyroxinemia 10.4 MECP2 SLC6A4
34 premature ovarian failure 1 10.4 EIF4E FMR1 MECP2 SLC6A4
35 active cochlear meniere's disease 10.4 GABRB3 SHANK3
36 attention deficit-hyperactivity disorder 10.4
37 chronic conjunctivitis 10.3 GABRB3 SHANK3 SLC6A4
38 epilepsy 10.3
39 craniosynostosis, adelaide type 10.3 CNTNAP2 FMR1 MECP2 SLC6A4 SLC9A9
40 familial partial lipodystrophy 10.2 GABRB3 NLGN3 NLGN4X SHANK3 SLC6A4
41 iris hypoplasia 10.2 CNTNAP2 FMR1 MECP2 PTCHD1 SHANK3
42 intracranial thrombosis 10.2 CNTNAP2 FOXP2
43 schizophrenia 10.1
44 bipolar disorder 10.1
45 mental retardation, autosomal dominant 26 10.0
46 colitis 10.0
47 personality disorder 10.0 FMR1 MECP2 SHANK3 SLC6A4 TOR3A
48 anxiety disorder 9.9
49 pandas 9.9
50 intellectual disability 9.9

Graphical network of the top 20 diseases related to Pervasive Developmental Disorder:



Diseases related to Pervasive Developmental Disorder

Symptoms & Phenotypes for Pervasive Developmental Disorder

UMLS symptoms related to Pervasive Developmental Disorder:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after Maraba virus infection GR00252-A-1 9.74 GABRB3 PTCHD1 SCT SHANK2 CHD8 FOXP2
2 Decreased viability after Maraba virus infection GR00252-A-2 9.74 PTCHD1 SCT SHANK2 CHD8 FOXP2 GABRB3
3 Decreased viability after Maraba virus infection GR00252-A-3 9.74 FOXP2

MGI Mouse Phenotypes related to Pervasive Developmental Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 CTNND2 FMR1 GABRB3 KCND2 MECP2 NLGN3
2 nervous system MP:0003631 9.36 CNTNAP2 CTNND2 FMR1 GABRB3 KCND2 MECP2

Drugs & Therapeutics for Pervasive Developmental Disorder

Drugs for Pervasive Developmental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
5
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
6
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
7
Milnacipran Approved Phase 4 92623-85-3 65833
8
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
9
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
10
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
11
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
12
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
13
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
14
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
15
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
16
Choline Approved, Nutraceutical Phase 4 62-49-7 305
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibodies Phase 4
23 gamma-Globulins Phase 4
24 Immunoglobulins Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Rho(D) Immune Globulin Phase 4
27 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
35 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antiviral Agents Phase 4,Phase 2
40 Respiratory System Agents Phase 4,Phase 2,Phase 3
41 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Adrenergic Agonists Phase 4,Phase 2
43 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
44 Adrenergic alpha-Agonists Phase 4,Phase 2
45 Antihypertensive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
46 Atomoxetine Hydrochloride Phase 4,Phase 3
47 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
48
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
49 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 613)

id Name Status NCT ID Phase Drugs
1 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
2 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
3 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
4 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
5 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
6 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
7 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
8 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
9 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
10 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
11 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
12 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
13 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
14 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
15 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Completed NCT01683565 Phase 4 LCPUFA oil supplement
16 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Recruiting NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
17 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
18 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4 N-Acetyl Cysteine
19 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Enrolling by invitation NCT02940574 Phase 4 Syntocinon (Oxytocin)
20 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4 Natrol
21 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
22 Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls Unknown status NCT02568631 Phase 2, Phase 3
23 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
24 D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Completed NCT01086475 Phase 3 D-cycloserine;Placebo
25 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) Completed NCT00261508 Phase 3 risperidone
26 Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3 Riluzole;placebo
27 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
28 Understanding Sleep Problems in Children With Autism Spectrum Disorder Completed NCT00691080 Phase 2, Phase 3
29 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
30 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
31 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00352352 Phase 3
32 Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder Completed NCT00352248 Phase 3
33 Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation Completed NCT00355329 Phase 3
34 Acamprosate in Youth With Fragile X Syndrome Completed NCT01300923 Phase 3 Acamprosate
35 Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders Completed NCT01021384 Phase 3
36 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
37 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
38 Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism Completed NCT01039792 Phase 2, Phase 3 Methyl B12
39 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3 Galantamine
40 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00332241 Phase 3 Aripiprazole;Placebo
41 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00337571 Phase 3 Aripiprazole;Placebo
42 Pharmacogenomics in Autism Treatment Completed NCT00584701 Phase 2, Phase 3 Risperidone
43 Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome Completed NCT01282268 Phase 3 arbaclofen;placebo
44 Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children Completed NCT00178503 Phase 2, Phase 3 Methylphenidate-extended release;Methylphenidate-immediate release
45 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER
46 Open Label Clinical Trial of Vitamin D in Children With Autism Completed NCT01535508 Phase 2, Phase 3 Liquid Vitamin D
47 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
48 Lurasidone Pediatric Autism Study Completed NCT01911442 Phase 3 Lurasidone 20 mg daily;Lurasidone;Placebo
49 Secretin for the Treatment of Autism Completed NCT00065962 Phase 3 secretin, synthetic porcine;secretin, biologically derived porcine
50 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders Recruiting NCT01302964 Phase 3 Placebo;Mirtazapine;Mirtazapine

Search NIH Clinical Center for Pervasive Developmental Disorder

Genetic Tests for Pervasive Developmental Disorder

Anatomical Context for Pervasive Developmental Disorder

MalaCards organs/tissues related to Pervasive Developmental Disorder:

39
Brain, Testes, Eye, Bone, Liver, Cortex, Bone Marrow

Publications for Pervasive Developmental Disorder

Articles related to Pervasive Developmental Disorder:

(show top 50) (show all 263)
id Title Authors Year
1
Neonatal factors among subjects diagnosed with a pervasive developmental disorder in the US. ( 28462601 )
2017
2
Autism Spectrum/Pervasive Developmental Disorder. ( 27262008 )
2016
3
Are There Differences in Neurocognition and Social Cognition Among Adolescents with Schizophrenia, a Pervasive Developmental Disorder, and Both Disorders? ( 27015370 )
2016
4
A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States. ( 26528457 )
2015
5
Hemispheric Processing of Idioms and Irony in Adults With and Without Pervasive Developmental Disorder. ( 26070277 )
2015
6
The Stability of Comorbid Psychiatric Disorders: A 7A Year Follow Up of Children with Pervasive Developmental Disorder-Not Otherwise Specified. ( 26456972 )
2015
7
Psychological interventions in pervasive developmental disorder: An overview. ( 25788797 )
2014
8
Examining the criterion-related validity of the Pervasive Developmental Disorder Behavior Inventory. ( 24463433 )
2014
9
Detecting Subgroups in Children Diagnosed with Pervasive Developmental Disorder - Not Otherwise Specified. ( 25374133 )
2014
10
Sensory hypersensitivity in children with high-functioning pervasive developmental disorder. ( 25803881 )
2014
11
Psychiatric comorbidity in children with high-functioning pervasive developmental disorder. ( 25272562 )
2014
12
A Case-Control Study Evaluating the Relationship Between Thimerosal-Containing Haemophilus influenzae Type b Vaccine Administration and the Risk for a Pervasive Developmental Disorder Diagnosis in the United States. ( 25382662 )
2014
13
Sunsetting DSM-IV's pervasive developmental disorder. ( 24745948 )
2014
14
Catatonic features in adolescents with schizophrenia with and without a comorbid pervasive developmental disorder. ( 24914405 )
2014
15
A comparison of DSM-IV pervasive developmental disorder and DSM-5 autism spectrum disorder prevalence in an epidemiologic sample. ( 24745950 )
2014
16
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( 24703761 )
2014
17
Psychiatric diagnostic screening of social maladaptive behaviour in children with mild intellectual disability: differentiating disordered attachment and pervasive developmental disorder behaviour. ( 23906477 )
2013
18
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. ( 24130822 )
2013
19
Pervasive developmental disorder in the children of immigrant parents: comparison of different assessment instruments. ( 24394875 )
2013
20
Comparison of pervasive developmental disorder and schizophrenia by the Japanese version of the National Adult Reading Test. ( 22335467 )
2013
21
Reduced brain activation during imitation and observation of others in children with pervasive developmental disorder: a pilot study. ( 23718943 )
2013
22
Brief report: An unusual manifestation of diagnostic overshadowing of pervasive developmental disorder--not otherwise specified: a five year longitudinal case study. ( 23108987 )
2013
23
Anxiety in children with high-functioning pervasive developmental disorder. ( 23909078 )
2013
24
Dual copy number variants involving 16p11 and 6q22 in a case of childhood apraxia of speech and pervasive developmental disorder. ( 22909776 )
2013
25
Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study. ( 23782127 )
2013
26
Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos: Comparative Observational Study and Literature Review. ( 24050746 )
2013
27
Inhibitory function and working memory in attention deficit/hyperactivity disorder and pervasive developmental disorders: does a continuous cognitive gradient explain ADHD and PDD traits? ( 24145729 )
2013
28
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. ( 23468071 )
2013
29
Executive function in children with pervasive developmental disorder and attention-deficit/hyperactivity disorder assessed by the Keio version of the Wisconsin card sorting test. ( 21917389 )
2012
30
Focal EEG abnormalities might reflect neuropathological characteristics of pervasive developmental disorder and attention-deficit/hyperactivity disorder. ( 22225922 )
2012
31
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. ( 23194148 )
2012
32
Sexual obsessions, compulsions, suicidality and homicidality in an adolescent diagnosed with bipolar disorder not otherwise specified, obsessive-compulsive disorder, pervasive developmental disorder not otherwise specified, and mild mental retardation. ( 22612525 )
2012
33
A case of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) coexisting with pervasive developmental disorder harboring SCN1A mutation in addition to CHRNB2 mutation. ( 23032131 )
2012
34
Is long-term prognosis for pervasive developmental disorder not otherwise specified different from prognosis for autistic disorder? Findings from a 30-year follow-up study. ( 21713590 )
2012
35
Is recovery from a pervasive developmental disorder possible? ( 22353321 )
2012
36
Multi-channel near-infrared spectroscopy shows reduced activation in the prefrontal cortex during facial expression processing in pervasive developmental disorder. ( 22250607 )
2012
37
Novel AGTR2 missense mutation in a Japanese boy with severe mental retardation, pervasive developmental disorder, and epilepsy. ( 22269148 )
2012
38
Using virtual reality environment to improve joint attention associated with pervasive developmental disorder. ( 22776822 )
2012
39
Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. ( 23032385 )
2012
40
Impact of attention deficit hyperactivity disorder-like symptoms on the clinical features of adolescents with pervasive developmental disorders. ( 23857705 )
2012
41
Epilepsy in pervasive developmental disorder without brain MRI abnormalities. ( 20863637 )
2011
42
Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. ( 21605498 )
2011
43
Toward specifying pervasive developmental disorder-not otherwise specified. ( 21298812 )
2011
44
Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism. ( 22174567 )
2011
45
Abnormal brain protein synthesis in language areas of children with pervasive developmental disorder: a L-[1-11C]-leucine PET study. ( 21636781 )
2011
46
New onset of psychotic symptoms in an adolescent with pervasive developmental disorder, not otherwise specified. ( 21309699 )
2011
47
Is pervasive developmental disorder not otherwise specified less stable than autistic disorder? A meta-analysis. ( 21153874 )
2011
48
The relationship between race and challenging behaviours in infants and toddlers with autistic disorder and pervasive developmental disorder-not otherwise specified. ( 21732805 )
2011
49
A case of pervasive developmental disorder complicated by social anxiety disorder responding well to fluvoxamine therapy. ( 21769772 )
2011
50
Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified. ( 22136097 )
2011

Variations for Pervasive Developmental Disorder

Expression for Pervasive Developmental Disorder

Search GEO for disease gene expression data for Pervasive Developmental Disorder.

Pathways for Pervasive Developmental Disorder

Pathways related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.07 CNTNAP2 FMR1 MECP2 SHANK2
2
Show member pathways
12.02 GABRB3 KCND2 NLGN3 NLGN4X SHANK2 SHANK3
3 11.38 GABRB3 KCND2 SLC6A4
4
Show member pathways
11.37 NLGN3 NLGN4X SHANK2 SHANK3

GO Terms for Pervasive Developmental Disorder

Cellular components related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.8 CNTNAP2 CTNND2 FMR1 KCND2 NLGN4X
2 neuron projection GO:0043005 9.78 FMR1 SHANK2 SHANK3 SLC6A4
3 postsynaptic density GO:0014069 9.73 FMR1 NLGN4X SHANK2 SHANK3
4 synapse GO:0045202 9.63 FMR1 GABRB3 KCND2 NLGN3 NLGN4X SHANK2
5 dendritic spine GO:0043197 9.62 FMR1 KCND2 SHANK2 SHANK3
6 perikaryon GO:0043204 9.56 CNTNAP2 CTNND2 FMR1 KCND2
7 postsynapse GO:0098794 9.54 FMR1 MECP2 NLGN3
8 mRNA cap binding complex GO:0005845 9.46 EIF4E FMR1
9 postsynaptic membrane GO:0045211 9.43 FMR1 GABRB3 KCND2 NLGN4X SHANK2 SHANK3
10 cell junction GO:0030054 9.23 CTNND2 FMR1 GABRB3 KCND2 NLGN3 NLGN4X

Biological processes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 memory GO:0007613 9.78 MECP2 SHANK2 SHANK3 SLC6A4
2 brain development GO:0007420 9.77 CHD8 CNTNAP2 MECP2 SCT SLC6A4
3 synapse assembly GO:0007416 9.73 MECP2 NLGN3 SHANK2 SHANK3
4 cerebellum development GO:0021549 9.71 FOXP2 MECP2 NLGN4X
5 long-term synaptic potentiation GO:0060291 9.71 MECP2 NLGN3 SHANK2 SHANK3
6 synapse organization GO:0050808 9.69 CTNND2 NLGN3 NLGN4X
7 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.67 NLGN3 SHANK2 SHANK3
8 adult behavior GO:0030534 9.65 CNTNAP2 NLGN3 NLGN4X SHANK2 SHANK3
9 positive regulation of excitatory postsynaptic potential GO:2000463 9.64 NLGN3 SHANK3
10 positive regulation of dendritic spine development GO:0060999 9.63 FMR1 SHANK3
11 brain morphogenesis GO:0048854 9.63 SHANK3 SLC6A4
12 thalamus development GO:0021794 9.63 CNTNAP2 PTCHD1 SLC6A4
13 learning GO:0007612 9.63 CNTNAP2 MECP2 NLGN3 NLGN4X SHANK2 SHANK3
14 dendritic spine morphogenesis GO:0060997 9.62 CTNND2 SHANK3
15 long term synaptic depression GO:0060292 9.62 SHANK2 SHANK3
16 exploration behavior GO:0035640 9.61 SHANK2 SHANK3
17 regulation of dendritic spine morphogenesis GO:0061001 9.61 NLGN3 SHANK3
18 neuron cell-cell adhesion GO:0007158 9.6 NLGN3 NLGN4X
19 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.59 MECP2 NLGN3
20 negative regulation of excitatory postsynaptic potential GO:0090394 9.58 NLGN3 NLGN4X
21 presynaptic membrane assembly GO:0097105 9.58 NLGN3 NLGN4X
22 inhibitory postsynaptic potential GO:0060080 9.57 GABRB3 NLGN3
23 regulation of long-term synaptic potentiation GO:1900271 9.55 NLGN3 SHANK3
24 positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity GO:2000969 9.52 NLGN3 SHANK3
25 vocal learning GO:0042297 9.5 CNTNAP2 FOXP2 SHANK3
26 vocalization behavior GO:0071625 9.35 CNTNAP2 NLGN3 NLGN4X SHANK2 SHANK3
27 postsynaptic membrane assembly GO:0097104 9.26 NLGN3
28 social behavior GO:0035176 9.23 CNTNAP2 MECP2 NLGN3 NLGN4X PTCHD1 SHANK2

Molecular functions related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neurexin family protein binding GO:0042043 9.26 NLGN3 NLGN4X
2 siRNA binding GO:0035197 9.16 FMR1 MECP2
3 scaffold protein binding GO:0097110 9.13 NLGN3 NLGN4X SHANK3
4 GKAP/Homer scaffold activity GO:0030160 8.62 SHANK2 SHANK3

Sources for Pervasive Developmental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....